PROVECTUS BIOPHARMACEUTICALS, INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
PVCT$0.04-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | ||||
| 2026 · 2025 | ||||
| Cash Flows From Operating Activities: | ||||
| Net loss | $(3,563,375) | $(4,337,312) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 921,301 | 949,945 | ||
| Non-cash operating lease expense | 36,341 | 36,305 | ||
| Depreciation | 1,397 | 1,398 | ||
| Changes in operating assets and liabilities | ||||
| Prepaid expenses and other current assets | 181,999 | 390,778 | ||
| Accounts payable | (112,216) | 71,225 | ||
| Unearned grant revenue | - | (336,108) | ||
| Accrued interest | 160,696 | 155,064 | ||
| Other accrued expenses | 834,114 | 648,909 | ||
| Operating lease liability | (35,666) | (36,642) | ||
| Net Cash Used In Operating Activities | (1,575,409) | (2,456,438) | ||
| Cash Flows From Financing Activities: | ||||
| Proceeds from issuance of convertible notes payable | 1,355,000 | 550,000 | ||
| Proceeds from issuance of convertible notes payable - related parties | 340,000 | 975,000 | ||
| Proceeds from issuance of common stock of majority-owned subsidiary | 75,000 | 700,000 | ||
| Repayment of notes payable | (240,705) | (186,223) | ||
| Repayment of convertible note payable – related party | (25,000) | - | ||
| Net Cash Provided By Financing Activities | 1,504,295 | 2,038,777 | ||
| Effect of exchange rates on cash | 556 | 414 | ||
| Net Decrease In Cash | (70,558) | (417,247) | ||
| Cash, Beginning of Period | 251,291 | 489,726 | ||
| Cash, End of Period | $180,733 | $72,479 | ||
| Supplemental Disclosures of Cash Flow Information: | ||||
| Cash paid during the period for: | ||||
| Interest | $4,222 | $4,305 | ||
| Income taxes | $ | - | $ | - |
| Non-cash investing and financing activities: | ||||
| Conversion of 2022 Notes and related accrued interest to Series D-1 Preferred Stock | $ | - | $1,770,603 | |
| Conversion of 2024 Notes and related accrued interest to Series D-1 Preferred Stock | $ | - | $718,565 | |
| Conversion of 2025 Notes and related accrued interest to Series D-1 Preferred Stock | $1,647,666 | $ | - | |
| Conversion of accrued directors’ fees to Series D-1 Preferred Stock | $542,501 | $ | - | |
| Right-of-use asset obtained in exchange for operating lease liability | $ | - | $150,133 | |
| Purchase of insurance policies financed by short-term note payable | $(59,880) | $(71,904) | ||
| Prepaid software financed by note payable | $ | - | $(95,070) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.